- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
On October 27, 2016, biotech experts and industry professionals will converge on London to discuss the sector’s outlook.
On October 27, 2016, biotech experts and industry professionals will converge on London. Their purpose? To discuss R&D challenges from a UK perspective, as well as consider how the biotech sector might respond to Brexit.
FierceBiotech is hosting the event, which takes place at the Royal Society of Medicine. The conference consists of two panels and a fireside chat, where topics up for debate will include the role of NICE in drug pricing, current industry trends and the anticipated impact of Brexit on Britain’s biotech sector.
What is England’s influence on drug-pricing worldwide?
How can the country attract biotech investment post-Brexit?
Why is the clinical trial process changing … and what might it look like in the future?
These questions, and others like them, will be considered by an esteemed group of industry experts. Speakers and panelists include Joanne Hulbert, a director of global regulatory affairs at PRA Health Sciences; Divya Chadha Manek, the Head of Commercial Business Development at the NIHR Clinical Research Network; and Dr. Jonathan Flelden, Director of Specialized Commissioning and Deputy Nation Medical Director at NHS England.
Register now for the event. But if you’re not lucky enough to attend? Never fear. We’ll be live tweeting the conference, so stay tuned to @INN_LifeScience for real-time updates.
And make sure to check back here following the event—you can bet we’ll be covering all of the major takeaways in detail!
Don’t forget to follow us @INN_LifeScience for conference updates.
Securities Disclosure: I, Chelsea Pratt, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â